Policy & Regulation
Eisai to appeal EU negative opinion on Alzheimer's drug
26 July 2024 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its partner Eisai Co Ltd (TYO:4523) announced on Friday that they intend to appeal the negative opinion on lecanem...
CStone wins EU approval for lung cancer drug
26 July 2024 - Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy fo...
AbbVie receives EU approval for SKYRIZI in ulcerative colitis
26 July 2024 - Pharmaceutical research & development company AbbVie (NYSE:ABBV) on Friday announced European Commission approval for SKYRIZI (risankizumab) for the treatment of moderately to sever...
Calliditas reports positive Phase 2b data
26 July 2024 - Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) on Friday reported positive topline data from its Phase 2b TRANSFORM trial evaluating setanaxib, a NOX enzyme inhibitor,...
Innovent Biologics and WeComput enter strategic partnership
26 July 2024 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Thursday that it has partnered with WeComput, a Chinese company that says it integrates art...
Presage Biosciences starts Phase 0 dosing of first cancer patient with Pure Biologics' PBA-0405
26 July 2024 - Presage Biosciences, a US-based biotechnology company that directly measures activity of oncology drugs within human tumours, announced on Thursday that it has commenced Phase 0 dosing ...